<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>International Journal of Radiation Research</title>
<title_fa>نشریه پرتو پژوه</title_fa>
<short_title>Int J Radiat Res</short_title>
<subject>Basic Sciences</subject>
<web_url>http://ijrr.com</web_url>
<journal_hbi_system_id>79</journal_hbi_system_id>
<journal_hbi_system_user>journal79</journal_hbi_system_user>
<journal_id_issn>2322-3243</journal_id_issn>
<journal_id_issn_online>2345-4229</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.61882/ijrr</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1401</year>
	<month>10</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2023</year>
	<month>1</month>
	<day>1</day>
</pubdate>
<volume>21</volume>
<number>1</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Postoperative intensity-modulated radiotherapy and chemotherapy in patients with high-grade glioma: analysis of efficacy and prognostic factors</title>
	<subject_fa>Radiation Biology</subject_fa>
	<subject>Radiation Biology</subject>
	<content_type_fa>تحقيق بديع</content_type_fa>
	<content_type>Original Research</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;font-size:10pt&quot;&gt;&lt;span style=&quot;text-justify:newspaper&quot;&gt;&lt;span style=&quot;text-kashida-space:50%&quot;&gt;&lt;span style=&quot;line-height:119%&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;Background&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;To determine the treatment efficacy and prognostic factors for&amp;nbsp;high-grade glioma (HGG) patients treated&amp;nbsp;with postoperative intensity-modulated radiotherapy&amp;nbsp;(IMRT). &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;Materials and Methods:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;An&amp;nbsp;analysis&amp;nbsp;of&amp;nbsp;86 HGG patients who underwent surgery, radiotherapy (total&amp;nbsp;dose:&amp;nbsp;54-60&amp;nbsp;Gy),&amp;nbsp;and&amp;nbsp;chemotherapy&amp;nbsp;was&amp;nbsp;performed&amp;nbsp;retrospectively. The primary&amp;nbsp;endpoint was Overall&amp;nbsp;survival&amp;nbsp;(OS), while the secondary&amp;nbsp;endpoint was progression-free survival (PFS).&amp;nbsp;Patient&amp;nbsp;factors, tumor characteristics, and treatments were&amp;nbsp;examined&amp;nbsp;for&amp;nbsp;their&amp;nbsp;prognostic&amp;nbsp;value.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt; Results:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;Among the enrolled patients, there were 22 patients&amp;nbsp;of grade III and 64 patients of grade IV. At the end of the study, 48&amp;nbsp;cases had died, and&amp;nbsp;66 cases had relapsed. The median OS was&amp;nbsp;24&amp;nbsp;months, while&amp;nbsp;the median PFS was&amp;nbsp;just 9&amp;nbsp;months.&amp;nbsp;The mean OS of patients with grade III and IV glioma was 41 months and 16 months, respectively. Patients had relative survival rates of 73.2%, 46.6%, and 27.0% at 1, 2, and 5 years. The most common type of tumor recurrence was relapse within the radiation field. Univariate analysis&amp;nbsp;indicated that sex, age, Karnofsky Performance Scale score (KPS),&amp;nbsp;Pathological grade, tumor location, surgical approach, and adjuvant chemotherapy cycles were predictive factors for OS (P&lt;&amp;nbsp;0.05). In contrast, sex, age,&amp;nbsp;pathological grade,&amp;nbsp;number of lesions, surgical approach, and adjuvant chemotherapy cycles were predictive factors for PFS&amp;nbsp;(P&amp;nbsp;&lt;&amp;nbsp;0.05).&amp;nbsp;According to multivariate analysis indicated that&amp;nbsp;pathological grade, surgical approach, and adjuvant chemotherapy&amp;nbsp;cycles were associated&amp;nbsp;with&amp;nbsp;longer OS&amp;nbsp;and&amp;nbsp;PFS&amp;nbsp;(P&lt; 0.05). &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;Conclusions:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;Grade III gliomas, total surgical resection, and adjuvant chemotherapy for more than six cycles were associated with more favorable survival outcomes in this study.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>High-grade glioma, radiotherapy, chemotherapy, prognostic factors, survival analysis.</keyword>
	<start_page>139</start_page>
	<end_page>145</end_page>
	<web_url>http://ijrr.com/browse.php?a_code=A-10-1-1017&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>H. </first_name>
	<middle_name></middle_name>
	<last_name>Zhu</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460023155</code>
	<orcid>7900319475328460023155</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Radiation Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200336, China</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>J. </first_name>
	<middle_name></middle_name>
	<last_name>Luo</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>judongluo@163.com </email>
	<code>7900319475328460023156</code>
	<orcid>7900319475328460023156</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Department of Radiotherapy, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, Changzhou, 213003, China</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
